FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Dermatology Drugs in Phase III Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tradipitant

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2020

            Details:

            Tradipitant antipruritic effects not seen in moderate or severe Atopic Dermatitis and the study did not meet its primary endpoint.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lebrikizumab

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly and Company

            Deal Size: $1,100.0 million Upfront Cash: $1,100.0 million

            Deal Type: Acquisition February 20, 2020

            Details:

            The acquisition of Dermira also expands Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA® (glycopyrronium).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ruxolitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 19, 2020

            Details:

            Building on the previously-reported positive topline results from TRuE-AD2, the results of TRuE-AD1 also show that significantly more patients treated with ruxolitinib cream achieved the IGA-TS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Roflumilast

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 13, 2020

            Details:

            Arcutis has enrolled the first patient in an open label extension study, DERMIS-OLE, evaluating topical roflumilast cream (ARQ-151) as a potential treatment for plaque psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naloxone Hydrochloride

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2020

            Details:

            The Phase III SPIRIT-2 trial is evaluating the safety and efficacy of naloxone lotion for relief of pruritus (itching) associated with Cutaneous T-Cell Lymphoma .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenabasum

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jefferies

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 06, 2020

            Details:

            Corbus intends to use the net proceeds to fund its continued development of lenabasum, CRB-4001 and its other preclinical compounds as well as for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Daxibotulinumtoxin A

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 06, 2020

            Details:

            Biologics License Application for DAXI in the treatment of moderate to severe glabellar lines has been accepted for review by the U.S. Food and Drug Administration (FDA).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Berdazimer sodium

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 06, 2020

            Details:

            Novan has been granted a Type C meeting with the U.S. FDA on April 1, 2020. Last subject completes last visit, Week 24 safety evaluation in company’s Phase 3 B-SIMPLE program with SB206.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Upadacitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 05, 2020

            Details:

            In this large Phase 3 study, RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ruxolitinib

            Therapeutic Area: Dermatology

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 28, 2020

            Details:

            The study was testing the ruxolitinib cream in adolescent and adult patients aged 12 years and above.

            PharmaCompass